Patient demographics, MRI results, and biopsy results
| Total patients | 33 |
| Patients with any prostate cancer, n (%) | 18 (54.6) |
| Patients with clinically significant prostate cancer, n (%) | 8 (24.2) |
| Median (IQR) prebiopsy PSA level, ng/mL | 7.0 (5.1–11.4) |
| Median (IQR) prebiopsy prostate volume, mL | 47 (39–66) |
| Median (IQR) age, years | 67 (59–71) |
| Race/ethnicity, n (%) | |
| Decline | 11 (33.3) |
| White | 11 (33.3) |
| Black | 2 (6.1) |
| Asian | 3 (9.9) |
| Other | 6 (18.2) |
| Clinical history, n (%) | |
| Biopsy naïve | 14 (42.4) |
| Active surveillance | 6 (18.2) |
| Prior negative biopsy | 10 (30.3) |
| Post-partial gland cryoablation | 3 (9.1) |
| Median (IQR) systematic cores taken | 9 (2–12) |
| Median (IQR) targeted cores taken | 4 (2–6) |
| Tumor characteristics | |
| Number of ROIs, total | 47 |
| MRI Grades (PI-RADS v2 Score), total, n (%) | |
| 3 | 16 (34.0) |
| 4 | 25 (53.2) |
| 5 | 6 (12.8) |
| Highest Gleason Grade Group, n (%) | |
| Benign | 15 (45.6) |
| 1 | 10 (30.3) |
| 2 | 6 (18.2) |
| 3 | 1 (3.0) |
| 4 | 0 (0) |
| 5 | 1 (3.0) |
| Complications, n (%) | 3 (9.1) |
| Hematuria | 2 (6.1) |
| Urinary retention | 1 (3.0) |
PI-RADS, Prostate Imaging-Reporting and Data System; PSA, prostate specific antigen.